Skip to content

Clinical trials

Phase 1 Bronchiolitis Obliterans Syndrome trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Bronchiolitis Obliterans Syndrome Phase: Phase 1 Clear all

50 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20031
20041
20073
20082
20092
20103
20114
20124
20134
20153
20161
20171
20183
20192
20202
20211
20221
20242
20255
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed25
Recruiting8
Terminated4
Withdrawn4
Active, not recruiting3
Unknown status3
Not yet recruiting2
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Hoffmann-La Roche4
Dana-Farber Cancer Institute3
Amgen2
Children's Hospital Medical Center, Cincinnati2
City of Hope Medical Center2
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine2
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)1
AstraZeneca1
Ausper Biopharma Co., Ltd.1
Bristol-Myers Squibb1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Bronchiolitis Obliterans Syndrome50
Graft vs Host Disease7
Leukemia5
Hepatitis C4
Lymphoma4
Neoplasms4
Leukemia, Lymphocytic, Chronic, B-Cell3
Lymphoma, Follicular3
Lymphoma, Large B-Cell, Diffuse3
Multiple Myeloma3

Trials

Showing 26 to 50 of 50. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.